Cancer is an abnormal growth of cells the proximate cause of which is an imbalance in cell proliferation and death breaking-through the normal physiological checks and balances system and the ultimate cause of which are one or more of a variety of gene alterations. These alterations can be structural, e.g., mutations, insertions, deletions, amplifications, fusions and translocations, or functional (heritable changes without changes in nucleotide sequence). No single genomic change is found in all cancers and multiple changes (heterogeneity) are commonly found in each cancer generally independent of histology. In healthy adults, the immune system may recognize and kill the cancer cells or allow a non-detrimental host-cancer equilibrium; unfortunately, cancer cells can sometimes escape the immune system resulting in expansion and spread of these cancer cells leading to serious life threatening disease. Approaches to cancer gene therapy include three main strategies: the insertion of a normal gene into cancer cells to replace a mutated (or otherwise altered) gene, genetic modification to silence a mutated gene, and genetic approaches to directly kill the cancer cells.
Furthermore, approaches to cellular cancer therapy currently largely involve the infusion of immune cells designed to either (i) replace most of the patients own immune system to enhance the immune response to cancer cells, (ii) activate the patients own immune system (T cells or Natural Killer cells) to kill cancer cells, or (iii) to directly find and kill the cancer cells. Moreover, genetic approaches to modify cellular activity further alter endogenous immune responsiveness against cancer.
Currently, multiple promising clinical trials using these gene and cell based approaches are ongoing in Phase I through Phase III testing in patients with a variety of different types of cancer.
Cancer is a process in which cells grow aberrantly. The growth of cancer cells leads to damage of normal tissues, causing loss of function and often pain. Many types of tumors shed cells that migrate to other distant sites in the body, establish a base there, and grow continuously. These secondary cancer sites, called metastases, cause local destruction, loss of normal tissue function and can acquire an even greater propensity to shed. Multiple cumulative genetic and/or epigenetic changes are needed to cause cancer. Those genes on which the maintenance of the cancer process depends are called driver genes which, unlike passenger genes, are key targets although non-driver genes can also contribute to cancer growth.
A number of gene therapy strategies are being evaluated in patients with cancer and these include manipulating cells to gain or lose function. For example, half of all cancers have a mutated p53 protein that interferes with the ability of tumor cells to self-destruct by a process called apoptosis. To this end, investigators are currently testing in clinical trials the ability to genetically introduce a normal p53 gene into these cancer cells. Introduction of a normal p53 gene renders the tumor cells more sensitive to standard chemotherapy and radiation treatments compared to tumor cells expressing the abnormal protein. Furthermore, other tumor suppressor genes are being placed in gene cassettes for expression in tumor cells, which can similarly render them more sensitive to apoptosis, or the process of programmed cell death. Other investigators are utilizing gene therapy approaches to induce expression of immune stimulating proteins called cytokines which in turn may increase the ability of the patients own immune system to recognize and kill these cancer cells. Another immune modulating alternative entering the clinic is the use of RNA interference (RNAi) silencing of endogenous cancer intracellular immune suppressor proteins, e.g., TGF beta, as a component of immunotherapy.
Along this line, gene silencing has been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth (with particular attention to presumptive driver genes), blood vessel formation, seeding of tumor cells to other tissues, and allow for resistance to chemotherapy. Several such genes, termed oncogenes, are often expressed continuously at high concentrations in cancer cells and express proteins that increase cell growth and/or division. Alternatively, tumor growth requires new blood vessel formation to survive, a process known as angiogenesis, which is mediated by an array of interacting proteins. A number of approaches to gene silencing have been or are being explored in the clinic including anti-sense oligonucleotides (ASO), short interfering RNA (siRNA) and short hairpin RNA (shRNA) that target post-transcription mRNA, and bi-functional shRNA which has both post-transcriptional silencing and translation-inhibitory effects.
Furthermore, tumor cells can loose intercellular cohesion, enter the bloodstream and seed other tissues, enabled by epithelial-mesenchymal transition, where they can undergo mesenchymal-epithelial transition and grow at the newly seeded site; once again mediated by a different set of genes. Finally, scientists have identified genes in tumor cells, which allow for these tumor cells to escape killing by chemotherapy. Therefore, an alternative gene therapy approach for cancer is to target one or more of these genes in order to suppress or silence their expression resulting in an inability of these tumor cells to either maintain cell growth, inhibit metastases, impair blood vessel formation, or reverse drug resistance. Mesenchymal stem cells, which have cancer-trophic migratory properties, are being engineered to express anti-proliferative, anti-EMT, and anti-angiogenic agents.
Alternatively, gene therapy approaches may be designed to directly kill tumor cells using tumor-killing viruses, or through the introduction of genes termed suicide genes into the tumor cells. Scientists have generated viruses, termed oncolytic viruses, which grow selectively in tumor cells as compared to normal cells. For example, an expanding number of human viruses such as measles virus, vesticular stomatitis virus, reovirus, adenovirus, and herpes simplex virus (HSV) can be genetically modified to grow in tumor cells with consequent cell kill, but very poorly in normal cells thereby establishing a therapeutic advantage. . Oncolytic viruses spread deep into tumors to deliver a genetic payload that destroys cancerous cells. Several viruses with oncolytic properties are naturally occurring animal viruses (Newcastle Disease Virus) or are based on an animal virus such as vaccinia virus (cow pox virus or the small pox vaccine). A few human viruses such as coxsackie virus A21 are similarly being tested for these properties. In addition, oncolytic viruses can be genetically modified (i.e. GM-CSF DNA transfer)so as to enhance immunogenicity (e.g., HSV). The combination of selective oncolytic cell death with release of danger-associated molecular-patterns and tumor-associated antigens with heightened immunogenicity has been shown both enhanced local and spatially additive effects. Currently, multiple clinical trials are recruiting patients to test oncolytic viruses for the treatment of various types of cancers.
Suicide genes encode enzymes that are produced in tumor cells to convert a nontoxic prodrug into a toxic drug. Examples of suicide enzymes and their prodrugs include HSV thymidine kinase (ganciclovir), Escherichia coli purine nucleoside phosphorylase (fludarabine phosphate), cytosine deaminase (5-fluorocytosine), cytochrome p450 (cyclophosphamide), cytochrome p450 reductase (tirapazamine), carboxypeptidase (CMDA), and a fusion protein with cytosine deaminase linked to mutant thymidine kinase. Significantly, prior pilot studies suggested that the treatment of the prostate cancer cells with the suicide genes introduced by the oncolytic virus increased cancer cell sensitivity to radiation and chemotherapy.
Most of the above approaches have the limitation that they require delivery of a "corrective" gene to every cancer cell, a demanding task. An alternative is to harness the immune system, which may have an ability to actively seek out cancer cells. In healthy adults, the immune system recognizes and kills precancerous cells as well early cancer cells, but cancer progression is an evolutionary process and results in large part from an immune-evasive adaptive response to the cancer microenvironment affecting both the afferent and efferent arms of the immune response arc. This results in inhibition of the ability of a patients immune system to target and eradicate the tumor cells. To this end, investigators are developing and testing several cell therapy strategies to correct impairment of the host-cancer immune interaction and as a consequence, to improve the immune systems ability to eliminate cancer.
Cell therapy for cancer refers to one or more of 3 different approaches: (i) therapy with cells that give rise to a new immune system which may be better able to recognize and kill tumor cells through the infusion of hematopoietic stem cells derived from either umbilical cord blood, peripheral blood, or bone marrow cells, (ii) therapy with immune cells such as dendritic cells which are designed to activate the patients own resident immune cells (e.g. T cells) to kill tumor cells, and (iii) direct infusion of immune cells such as T cells and NK cells which are prepared to find, recognize, and kill cancer cells directly. In all three cases, therapeutic cells are harvested and prepared in the laboratory prior to infusion into the patient. Immune cells including dendritic cells, T cells, and NK cells, can be selected for desired properties and grown to high numbers in the laboratory prior to infusion. Challenges with these cellular therapies include the ability of investigators to generate sufficient function and number of cells for therapy.
Clinical trials of cell therapy for many different cancers are currently ongoing. More recently, scientists have developed novel cancer therapies by combining both gene and cell therapies. Specifically, investigators have developed genes which encode for artificial receptors, which, when expressed by immune cells, allow these cells to specifically recognize cancer cells thereby increasing the ability of these gene modified immune cells to kill cancer cells in the patient. One example of this approach, which is currently being studied at multiple centers, is the gene transfer of a class of novel artificial receptors called chimeric antigen receptors or CARs for short, into a patients own immune cells, typically T cells. Investigators believe that this approach may hold promise in the future for patients many different types of cancer. To this end, multiple pilot clinical trials for a variety of cancer types using T cells genetically modified to express tumor specific CARs are ongoing, some of which are showing promising results.
See the rest here:
Cancer Gene Therapy and Cell Therapy | ASGCT - American ...
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022